NCT00621361View on ClinicalTrials.gov

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

February 29, 2012

Conditions
Lung Cancer
Interventions
DRUG

AZD2171

Oral

DRUG

Etoposide

Intravenous

DRUG

Cisplatin

Intravenous

Trial Locations (4)

Unknown

Research Site, Sacramento

Research Site, Denver

Research Site, Kansas City

Research Site, Houston

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY